News
Market and company headlines
SRZNAll
Loading
14:00Oct 151 Story
08:00Oct 21 Story
04:00-14:00Sep 252 Stories
Unusual volume stocks are being observed in Friday's session.
Unusual volume stocks are being observed in Friday's session.
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; several other stocks also fell premarket.
00:00-04:00Sep 252 Stories
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54
HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $44 to $54.
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.
08:00-11:00Sep 242 Stories
The market is filled with gapping stocks in Thursday's session.
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Wondering what's happening in today's pre-market session?
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
05:00-08:00Sep 242 Stories
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Surrozen submitted an IND application to the FDA for SZN-8141 to treat diabetic macular edema, with trial data expected in late 2027.
Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000
U.S. stocks fell Thursday as tech slid; jobless claims beat estimates. Oil rose, while APUS surged 245% and BENF plunged 33%.
04:00Sep 241 Story
13:00Sep 161 Story
04:00-09:00Sep 82 Stories
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endo
Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema
Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening